Hepatitis C

Latest News

Cost-effectiveness of Total State Coverage for Hepatitis C Medications

By William V. Padula, PhD
Jonathan S. Levin, PhD

May 20th 2021

Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Nobel Prize

Discovery of Hepatitis C Virus Brings Nobel Prize

By Mary Caffrey

October 5th 2020

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

By Maggie L. Shaw

April 17th 2020

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

By Maggie L. Shaw

March 2nd 2020

From the Editorial Board: Jeffrey D. Dunn, PharmD, MBA

By Jeffrey D. Dunn, PharmD, MBA

February 15th 2020

More News

May 4th 2016

Deaths From Hepatitis C Virus Hit All-Time High, CDC Reports

CDC also published a separate study that found more people in the United States now die from hepatitis C than die from HIV or any other infectious disease. The report comes as The American Journal of Managed Care publishes a special issue on policy concerns over patient access to new therapies that cure HCV.

May 3rd 2016

The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients

Anupam B. Jena, MD, PhD Warren Stevens, PhD Yuri Sanchez Gonzalez, PhD Steven E. Marx, PharmD Timothy Juday, PhD Darius N. Lakdawalla, PhD Tomas J. Philipson, PhD

Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver failure.

May 3rd 2016

Improving HCV Cure Rates in HIV-Coinfected Patients - A Real-World Perspective

Seetha Lakshmi, MD Maria Alcaide, MD Ana M. Palacio, MD, MPH Mohammed Shaikhomer, MD Abigail L. Alexander, MS Genevieve Gill-Wiehl, BA Aman Pandey, BS Kunal Patel, BS Dushyantha Jayaweera, MD Maria Del Pilar Hernandez, MD

The authors examine real-world hepatitis C virus cure rates with direct-acting antivirals among patients coinfected with HIV.

May 3rd 2016

Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment

Gigi A. Moreno, PhD Karen Mulligan, PhD Caroline Huber, MPH Mark T. Linthicum, MPP David Dreyfus, DBA Timothy Juday, PhD Steven E. Marx, PharmD Yuri Sanchez Gonzalez, PhD Ron Brookmeyer, PhD Darius N. Lakdawalla, PhD

Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.

May 3rd 2016

Value of Expanding HCV Screening and Treatment Policies in the United States

Mark T. Linthicum, MPP Yuri Sanchez Gonzalez, PhD Karen Mulligan, PhD Gigi A. Moreno, PhD David Dreyfus, DBA Timothy Juday, PhD Steven E. Marx, PharmD Darius N. Lakdawalla, PhD Brian R. Edlin, MD Ron Brookmeyer, PhD

Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.

May 3rd 2016

A Way Out of the Dismal Arithmetic of Hepatitis C Treatment

Jay Bhattacharya, MD, PhD Outcomes Research, Stanford University School of Medicine Guest Editor-in-Chief for the HCV special issue of The American Journal of Managed

This special issue presents important new peer-reviewed research, covering issues ranging from access and the out-of-pocket costs of a treatment course, to the real-world consequences-both economic and clinical-of failing to treat.

May 3rd 2016

Sofosbuvir Initial Therapy Abandonment and Manufacturer Coupons in a Commercially Insured Population

Taruja D. Karmarkar, MHS Catherine I. Starner, PharmD Yang Qiu, MS Kirsten Tiberg, RPh Patrick P. Gleason, PharmD

Member cost negatively affects initial medication adherence and manufacturer coupons can decrease member share by up to 98%.

May 3rd 2016

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD Haesuk Park, PhD Stuart C. Gordon, MD John R. Ferguson Aijaz Ahmed, MD Douglas Dieterich, MD Sammy Saab, MD, MPH

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

May 3rd 2016

Coverage for Hepatitis C Drugs in Medicare Part D

Jeah Kyoungrae Jung, PhD Roger Feldman, PhD Chelim Cheong, PhD Ping Du, MD, PhD Douglas Leslie, PhD

This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.

May 3rd 2016

Does Patient Cost Sharing for HCV Drugs Make Sense?

Darius N. Lakdawalla, PhD Mark T. Linthicum, MPP Jacqueline Vanderpuye-Orgle, PhD

Despite the high cost of novel hepatitis C treatments and patients' apparent willingness to bear part of it, high patient cost sharing is both inefficient and inequitable.

April 29th 2016

What We're Reading: Consumer Organization Files Lawsuit Against the FDA

What We’re Reading, April 29, 2016: While sales of Gilead's Harvoni drop, NY state attorney's decision could be good news for the company; and the FDA faces a lawsuit from a consumer advocacy group.

April 26th 2016

What We're Reading: SCOTUS Could Rule Big Against Pharmaceutical Industry

What we're reading, April 26, 2016: the Supreme Court could rule for new process of reviewing drug patents; new Medicaid rules announced; 7 New York insurers will expand coverage of hepatitis C drugs.

This Week in Managed Care: March 19, 2016

March 19th 2016

This Week in Managed Care: March 19, 2016

This week, the top managed care stories include Humana announcing executive bonuses are now partially tied to value, Veterans Affairs has expanded access of hepatitis C drugs to all veterans in the system, and CDC releases guidelines on prescribing opioids.

March 14th 2016

VA Will Treat All Veterans for HCV Regardless of Disease Stage

Laura Joszt, MA

The Department of Veterans Affairs will now be able to treat all veterans who have hepatitis C instead of restricting treatment to only the sickest.

March 9th 2016

Cancer Deaths Drop, With Liver Cancer the Exception

The report found higher death rates from liver cancer among the age group most at risk for hepatitis C virus, those born between 1945 and 1965. But increased rates of diabetes, obesity, and alcohol use are to blame for rising liver cancer deaths as well.

March 1st 2016

What We're Reading: New HCV Drug Fails to Generate Excitement

What we're reading, March 1, 2016: physicians greet Merck's new hepatitis C drug with caution; 20% of Puerto Ricans could be infected with the Zika virus in 2016; and nearly $3 billion wasted in cancer medicines.

February 21st 2016

Comparing 3 Direct-Acting Antiviral Agents for HCV: A Review of the Evidence

A review of evidence of the clinical safety and efficacy of Zepatier found that the hepatitis C virus treatment appears to have a less risky safety profile than Sovaldi and a similar safety profile as Harvoni.

February 18th 2016

What We're Reading: Some Clinical Trial Results Are Never Disclosed

What we're reading, February 18, 2016: one-third of clinical trial results are never published; Sandoz challenges rule for notices of biosimilar launches; and hepatitis C combination drug could reduce treatment to just 4 weeks.

January 29th 2016

What We're Reading: Merck's New HCV Drug Increases Competition

What we're reading, January 29, 2016: newly approved hepatitis C cure will increase competition; California will vote on a proposition to control the cost of prescription drugs; and a special report details drug shortages and rationing decisions.

January 28th 2016

What We're Reading: Can a State Sue Gilead Over the High Price of Its HCV Drugs?

What we're reading, January 28, 2016: Massachusetts' attorney general is threatening to sue Gilead Sciences over the high prices of its hepatitis C drugs; Anthem reports losses on Obamacare health plans; and consumers are satisfied with health coverage and limited networks.

November 30th 2015

Blue Cross Sued Over Denying Patients Hepatitis C Treatment

Laura Joszt, MA

In California, a class action lawsuit has been filed on behalf of thousands of Blue Cross beneficiaries living with hepatitis C who were denied treatment.

November 26th 2015

Top Hepatitis C Articles for the Year

Here are the top 5 papers published by The American Journal of Managed Care and its sister publications about hepatitis C, treatment, and costs of care.

November 24th 2015

What We're Reading: Treating Earlier With Pricey HCV Drugs

What we're reading, November 24, 2015: expensive hepatitis C drugs are more cost effective when used earlier; clinicians aren't prescribing generics enough; and half of health 45-year-olds will develop prediabetes.

August 7th 2015

Urban Emergency Departments Play a Critical Role in Identifying Undiagnosed HCV Patients

Surabhi Dangi-Garimella, PhD

An emergency department screening and testing program based on birth cohort screening and injectable drug use found a high prevalence of the hepatitis C virus antibody among the cohorts tested, and identified several barriers to clinical implementation of the process.

July 29th 2015

Treating 10% of California's Hep C Patients Could Cost the State Billions, Estimates CAHP Report

Surabhi Dangi-Garimella, PhD

A report released by the California Association of Health Plans projects a huge cost expenditure even if a small proportion of the state's hep C patients are treated with the potentially curative medications.

July 22nd 2015

Express Scripts' Miller Discusses Loss of "Social Contract" in Drug Pricing, Other Specialty Pharmacy Trends

The arrival of Sovaldi caused pharmacy benefit managers to adjust their strategies for controlling prices for breakthrough therapies. On the eve of a new drug class for cholesterol hitting the market, Express Scripts' Dr. Steve Miller tells Evidence-Based Diabetes Management in an interview how the PBM is working on behalf of managed care in a changed environment.

July 21st 2015

On Lessons Learned: Express Scripts' Steve Miller, MD, Discusses HCV Experience, PCSK9 Inhibitors, and More

On the eve of FDA's deadline for acting on the first of an expensive new class of cholesterol therapies, the chief medical officer of the nation's largest pharmacy benefit manager weighs on what steps it is taking on behalf of customers in this changing landscape.

June 30th 2015

Medicaid Enrollees With Hepatitis C Face Reimbursement Challenges

Surabhi Dangi-Garimella, PhD

Heterogeneity in Medicaid coverage of the anti-viral agent sofosbuvir is rampant across the United States, with varying reimbursement criteria and lack of conformation to recommendations by professional infectious disease organizations.

March 30th 2015

Participating Faculty: Hemophilia: Managing the Cost of Care With a Focus on Patient Outcomes

March 24th 2015

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-The New and Evolving Standards of Care

Gary M. Owens, MD

<1 2 3 4 5 6 7 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions